BIO CEO plans to join FDA modernization advisory board under Trump...
John Crowley, CEO of the biotech advocacy group BIO, is slated to join a Trump administration advisory board focused on modernizing the FDA, according to a source familiar with the planning. A...
View ArticleXO Health launches as alternative health plans catch on
Swati Mathai knows it’s a weird time to be launching a health plan startup. The December killing of UnitedHealthcare CEO Brian Thompson laid bare the American public’s fury with ...
View ArticleHealth tech funding in 2025 kicks off with megarounds
Health tech fundraising is making a comeback in the new year after clocking five rounds of over $100 million each. Since the year began, kidney care-focused Evergreen Nephrology has raised ...
View ArticleBiohaven’s protein degrader is promising in early IgAN trial, heads straight...
Interim Phase 1 data on Biohaven’s protein degrader are strong enough that the biotech is planning to move the drug straight into pivotal trials in the kidney disease IgA nephropathy (IgAN). BHV-1400...
View Article#JPM25: Day 2 at the JP Morgan Healthcare Conference
We’re back for day 2 of JPM. This morning, we're paying close attention to news about the industry's biggest drugmakers. Jaimy Lee has a piece about Pfizer CEO Albert ...
View ArticleDaiichi Sankyo brings Glycotope antibody in-house for $132.5M
Daiichi Sankyo is spending $132.5 million to buy an antibody outright that it had already licensed from Glycotope. The one-off fee “satisfies” all milestone and royalty payments due to Glycotope under...
View ArticleAfter GSK deal, IDRx chair takes investing role at Curie.Bio
SAN FRANCISCO — Ben Auspitz, a veteran biotech investor and repeat entrepreneur, is reuniting with longtime collaborator Alexis Borisy and his "free the founders" startup accelerator Curie.Bio, they...
View ArticleHealth insurers, pharmacy giants sit out JP Morgan Healthcare Conference
For as long as I’ve been a healthcare reporter, the JP Morgan Healthcare Conference has served as a newsy way to start the new year. How the week plays out ...
View ArticleAnavex reports long-term Alzheimer's data for drug with history of scrutiny
Anavex Life Sciences is back with more data for a pill that it’s looking to get approved in a variety of neurodegenerative and CNS disorders, reporting long-term Phase 2/3 Alzheimer’s data Monday. The...
View ArticleCan the Pfizer machine fight back against an activist investor?
Pfizer says it’s back on track. After a tumultuous 2024 filled with more cost cuts, an activist investor, a pulled drug and executive changes, CEO Albert ...
View ArticleRegeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan
Plus, news about Bioptimus, RhyGaze, Grifols, subcutaneous Leqembi and Sling Therapeutics: Regeneron pours $119.5M into Truveta Series C: Regeneron will also work with the medical data research company...
View ArticleAustralia's BioCina and NovaCina join forces to make one CDMO
Private investment firm Bridgewest is combining its Australia-based biologics CDMO BioCina and its sterile injectable manufacturer NovaCina into one company. The new CDMO will continue to use the...
View ArticleRegenxbio sells Hunter syndrome license with FDA filing underway
Nippon Shinyaku has paid $110 million upfront for the rights to sell two of Regenxbio’s gene therapies for mucopolysaccharidosis in the US and Asia. The deal also provides for potential milestone fees...
View ArticleUmoja’s $100M Series C will advance its bid for more convenient cell therapies
In the 10th megaround of 2025, Umoja Biopharma has banked $100 million in a Series C fundraise with an eye to advancing its pipeline of in vivo CAR-T cell therapies for cancer and autoimmune diseases ...
View ArticleCharles River offers damp 2025 outlook for investors
Charles River Laboratories is predicting 2025 to be as tough as last year for CDMOs as pharma customers continue to cut costs with manufacturers. The company expects its revenue for 2025 to decline in...
View ArticleLykos upheaval continues with four new board exits
Four Lykos Therapeutics board members have stepped down, and another departed last month, in the aftermath of a stalemate over how to finance the psychedelic company's clinical future. The company...
View ArticleHHS inspector general raises concerns over three FDA accelerated approvals
The upheaval over the FDA's accelerated approval of Biogen's now-pulled Alzheimer's drug Aduhelm in 2021 led HHS' Office of Inspector General to review 24 other accelerated approvals to see if there...
View ArticleEli Lilly misses 2024 revenue expectations, stock dips 7%
Eli Lilly expects to miss its recent revenue estimate for 2024 by about $400 million, according to a preliminary report. The company’s estimates have varied widely this year. Lilly raised its 2024...
View ArticleSamsung Bio eyes construction of sixth manufacturing plant to kickstart 2025
Following a blockbuster 2024, Samsung Biologics is considering building a sixth manufacturing facility to meet the rising demand for biologics as it gears up to open its fifth site in April. During the...
View Article